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Abstract: Mucopolysaccharidosis IVA (MPS IVA) is caused by a deficiency of the lysosomal enzyme
N-acetylgalactosamine-6-sulfate sulfatase (GALNS). Conventional enzyme replacement therapy (ERT)
is approved for MPS IVA. However, the fact that the infused enzyme cannot penetrate avascular
lesions in cartilage leads to minimal impact on the bone lesion. Moreover, short half-life, high cost,
instability, and narrow optimal pH range remain unmet challenges in ERT. Thermostable keratanase,
endo-β-N-acetylglucosaminidase, has a unique character of a wide optimal pH range of pH 5.0–7.0.
We hypothesized that this endoglycosidase degrades keratan sulfate (KS) polymer in circulating
blood and, therefore, ameliorates the accumulation of KS in multiple tissues. We propose a novel
approach, Substrate Degradation Enzyme Therapy (SDET), to treat bone lesion of MPS IVA. We assessed
the effect of thermostable keratanase on blood KS level and bone pathology using Galns knock-out
MPS IVA mice. After a single administration of 2 U/kg (= 0.2 mg/kg) of the enzyme at 8 weeks of age
via intravenous injection, the level of serum KS was significantly decreased to normal range level,
and this suppression was maintained for at least 4 weeks. We administered 2 U/kg of the enzyme
to MPS IVA mice every fourth week for 12 weeks (total of 3 times) at newborns or 8 weeks of age.
After a third injection, serum mono-sulfated KS levels were kept low for 4 weeks, similar to that
in control mice, and at 12 weeks, bone pathology was markedly improved when SDET started at
newborns, compared with untreated MPS IVA mice. Overall, thermostable keratanase reduces the
level of KS in blood and provides a positive impact on cartilage lesions, demonstrating that SDET is a
novel therapeutic approach to MPS IVA.
Keywords: MPS IVA; GALNS; thermostable keratanase; keratan sulfate; skeletal dysplasia

1. Introduction
Mucopolysaccharidosis type IVA (MPS IVA, also called Morquio Syndrome type A; OMIM
253000) is an autosomal recessive disorder caused by a deficiency of the lysosomal enzyme
N-acetylgalactosamine-6-sulfate sulfatase (GALNS) [1–6]. GALNS involves the degradation of
glycosaminoglycans (GAG), keratan sulfate (KS), and chondroitin-6-sulfate (C6S). Deficiency of this
enzyme causes progressive accumulation of KS and C6S in systemic tissues, especially cartilage and its
extracellular matrix (ECM), leading to a devastating skeletal dysplasia with incomplete ossification
and successive imbalance of growth [4,7,8]. Clinical features of skeletal dysplasia in MPS IVA patients
include short neck, pectus carinatum, cervical spinal cord compression, laxity of joints, kyphoscoliosis,
coxa valga, disproportionate short trunk, and genu valgum. Airway compromise (tracheal obstruction),
spinal cord compression, and cardiovascular involvements are life-threatening problems to severe type
of MPS IVA patients [4,7,9–11].
Int. J. Mol. Sci. 2019, 20, 4139; doi:10.3390/ijms20174139
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Enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) coupled
with various surgical interventions are treatment options currently available for patients with MPS
IVA in clinical practice. ERT and HSCT are based on the principle of cross-correction that lysosomal
enzymes are uptaken into cells via the mannose-6-phosphate receptor. ERT for MPS IVA was approved
in 2014 by the Food and Drug Administration; however, several limitations are indicated: (1) weekly
infusions for 5–6 h, (2) high cost [12,13], and (3) rapid clearance (a short half-life time, 35 min) [14].
In addition, patients treated with ERT have not shown any improvement in hypermobile joints, skeletal
dysplasia, or bone pathology [11,15–17], as observed in MPS IVA mice treated with ERT [18,19]. Thus,
there is no proof that the current ERT provides an impact on bone pathology in MPS IVA, even after
long-term treatment [15,16,19]. Our study has shown that ERT did not improve the accumulation of
storage materials in chondrocytes from surgical remnants during 6–60 months of this therapy [11,15,16].
Moreover, even if ERT started in a severe type of patients with MPS IVA before two years of age,
Do Cao et al. and we did not observe the improvement of the bone growth and actual height [17,20].
HSCT for MPS IVA was approved in Japan in 1995 with the initial success of transplantation,
and at least four patients have been followed over 15–25 years [21]. Only one patient underwent one
surgical intervention during the follow-up years. HSCT may provide a better outcome than ERT in
patients with MPS IVA. Dr. Wang et al. and we have monitored 13 cases of MPS IVA patients treated
with HSCT and have demonstrated the improvement of pulmonary function, the activity of daily
living, bone mineral density, cardiovascular function, and laxity of joints, as well as reduction of the
number of the surgical procedures [15,21–24]. However, HSCT has several critical issues: (1) finding
the appropriate donor, (2) risks of graft versus host disease and rejection, (3) limited impact on bone
lesions, and (4) requirement of well-trained staffs and facilities. Therefore, effective and feasible therapy
for a bone lesion in MPS IVA is an unmet challenge.
In addition, recent studies have indicated that not only accumulated GAG within cells but that in
the neighboring ECM provide a critical role to lead to abnormal chondrogenesis and endochondral
ossification [25–28]. Degradation of KS occurs in a step-wise manner by removal or processing of
the terminal residue on the non-reducing end of this polymer chain, involving various enzymes
including GALNS, N-acetylglucosamine 6-sulfatase, β-N-acetylhexosaminidase, and β-galactosidase.
These exohydrolases degrade GAG in lysosomes within the cell since the lysosomal enzymes are active
only in an acidic environment with narrow pH range from 4.5 to 5.0. Current ERT does not directly
degrade accumulated KS in blood and ECM in multiple tissues, including bone and cartilage lesions.
We have purified a KS hydrolase, endo-β-N-acetylglucosaminidase from Bacillus circulans and
have identified a characterization of thermostability in this enzyme. Thus we named this enzyme,
thermostable keratanase [29]. Thermostable keratanase is uniquely active and stable over a broad
physiological pH range (pH: 5.0–7.0). Here, we propose a novel enzyme therapy by using thermostable
keratanase, a bacterial endo-β-N-acetylglucosaminidase, which can directly degrade KS polymer in
blood circulation. We have hypothesized that the elimination of KS polymer from the circulating blood
using thermostable keratanase consequently ameliorates the accumulation of KS in multiple tissues
and their ECM.
In this study, we have investigated the therapeutic efficacy of thermostable keratanase in skeletal
abnormality using MPS IVA mice. We termed our novel, innovative therapy as “substrate degradation
enzyme therapy (SDET).”
2. Results
2.1. Production, Purification, and Characterization of Thermostable Keratanase
The thermostable keratanase was purified from B. circulans cell body as described in materials and
methods. Total 450 U of keratanase was obtained using 3 steps of column chromatography. SDS-PAGE
analysis of the enzyme showed a single band corresponding to a Mr of 220,000 (Figure 1A). The finally
purified enzyme activity was 50.0 U/mL; the specific activity was 11.5 U/mg protein, and endotoxin
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2.3. Preliminary Toxicity Study of Thermostable Keratanase in Mice
To assess the toxicity of thermostable keratanase, groups of 6 male C57BL/6J mice received weekly
intravenous injections of 250 U/kg of thermostable keratanase for a total of 4 times. No mice died during
the experimental period, and no treatment-related changes were noted in body weight loss. In the
clinical observations on the day of each treatment, rapid shallow breathing, and/or decreased locomotor
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Figure 2. Serum and tissue glycosaminoglycan levels of MPS IVA mice after a single administration of
thermostable keratanase. MPS IVA mice at 8 weeks of age were treated with 2 U/kg of thermostable
keratanase intravenously, and PBS was administered in the untreated group. Serum samples were
collected from the superficial temporal vein at the time points of 8, 9, 10, 11, 12, and 16 weeks of age.
The level of mono-sulfated KS (A) and diHS-0S (B) was measured by LC-MS/MS; n = 4–5. The tissue
sample was collected from MPS IVA mice 24 h post-injection of thermostable keratanase, and the levels
of mono-sulfated KS in liver (C) and spleen (D) were measured by LC-MS/MS; n = 4. Statistics were
analyzed by unpaired t-test. Data are presented as mean ± SD. * p < 0.05 vs. untreated MPS IVA. HS:
heparan sulfate, KS: keratan sulfate, TSK: thermostable keratanase.
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2.5. Therapeutic Effects of Thermostable Keratanase in MPS IVA Mice
To evaluate the efficacy of thermostable keratanase in bone and cartilage lesions, MPS IVA mice
were treated with 2 U/kg of the enzyme intravenously every 4 weeks for a total of 3 times from neonatal
period to 12 weeks of age (newborn administration study).
In the neonatal administration study, serum levels of mono-sulfated KS in treated mice moderately
decreased, compared to those in untreated MPS IVA mice at 8 weeks of age and significantly decreased
at 12 weeks of age (Figure 3A). Serum diHS-0S levels were similar between untreated and treated mice
at 8 and 12 weeks of age (Figure 3B). The histopathologic scores in the treated group were lower than
in the untreated group at 12 weeks of age (Figure 3C). Severe vacuolization of chondrocytes (score 3)
was noted in 67% of the untreated group, while in 29% of the treated group. Moderate to minimal
disorganization of chondrocytes (score 2-1) was noted in 56%–33% of the untreated group, while in
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW
6 of 14
43%–14% of the treated group (Table 1).
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Tablekeratanase.
1. Pathological score in growth plate region of femur/tibia of MPS IVA mouse.

Score 0
(None)

Control
Untreated

Score 1
Score 2
Score 3
(Minimal)
(Moderate)
(Severe)
(a) Vacuolization of chondrocyte
100% (8/8)
0% (0/8)
0% (0/8)
0% (0/8)
0% (0/9)
0% (0/9)
33% (3/9)
67% (6/9)

Total Mouse
n
8
9
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Table 1. Pathological score in growth plate region of femur/tibia of MPS IVA mouse.
Score 0 (None)

Score 1
(Minimal)

Score 2
(Moderate)

Score 3
(Severe)

Total Mouse
n

0% (0/8)
67% (6/9)
29% (2/7)

8
9
7

0% (0/8)
0% (0/9)
0% (0/7)

8
9
7

(a) Vacuolization of chondrocyte
Control
Untreated
Treated

100% (8/8)
0% (0/9)
0% (0/7)

0% (0/8)
0% (0/9)
14% (1/7)

0% (0/8)
33% (3/9)
57% (4/7)

(b) Disorganization of column structure
Control
Untreated
Treated

100% (8/8)
11% (1/9)
43% (3/7)

0% (0/8)
33% (3/9)
14% (1/7)

0% (0/8)
56% (5/9)
43% (3/7)

(a) Vacuolization of chondrocyte in proliferative lesion: Score 0 (None), Not observed; Score 1 (Minimal), <20%;
Score 2 (Moderate), 20%–50%; Score 3 (Severe), >50%. (b) Disorganization of column structure in proliferative lesion:
Score 0 (None), Not observed; Score 1 (Minimal), <20%; Score 2 (Moderate), 20%–50%; Score 3 (Severe), >50%.

3. Discussion
The goal of this study was to evaluate the therapeutic efficacy of thermostable keratanase,
a bacterial endoglycosidase, in MPS IVA mice. We have demonstrated that thermostable keratanase
into MPS IVA mice provided an impact on (i) a significant reduction (normalization) in levels of
serum KS and (ii) a decrease in vacuolation of proliferative zone chondrocytes in the growth plates.
Thus, thermostable keratanase showed therapeutic efficacy in cartilage, in which ERT has shown very
limited efficacy [18,19,31]. After a single administration of thermostable keratanase to MPS IVA mice at
8 weeks of age, the levels of serum KS were immediately decreased and normalized. This reduction of
KS suggests that thermostable keratanase directly clears KS in the blood since this enzyme has a wide
optimal pH range from 5.0–7.0. This KS reduction was maintained for at least 4 weeks; indeed, every
4 weeks for a total of 3 times administration of thermostable keratanase resulted in a lower degree of
vacuolization in the chondrocytes in the treated group than that of the untreated group in the neonatal
administration study.
On the other hand, our previous study in MPS IVA mice treated with recombinant human GALNS
showed that the levels of KS in blood were not normalized to the wild type level even after 12 weekly
ERT [18]. Overall, these findings demonstrate that SDET is superior to ERT in not only therapeutic
efficacy but the less frequency of administration.
Additionally, current ERT degrades accumulated GAGs only in lysosomes within the cells but
not accumulated GAGs in ECM due to its optimal acidic pH. There is, however, a possibility that
thermostable keratanase penetrated the ECM of the cartilage and directly degraded the accumulated
KS as with the enzyme directly degraded KS in the circulating blood. In fact, we have found that KS
levels in bone and other tissues were significantly reduced compared with untreated MPS IVA mice
after thermostable keratanase twice infusions at day 0 or 1 and 2 weeks old. This suggests that KS
in ECM has been degraded (in progress, data not shown). Further study of the tissue distribution of
administered thermostable keratanase is required to confirm this possibility.
Recent studies have shown that inflammation plays an important role in the pathophysiology of
MPS. The fragments of excessive GAG released in ECM stimulate toll-like receptor 4 (TLR4) [32,33].
Activation of NF-κB signaling via TLR4 resulted in the production of various inflammatory cytokine
and protease such as TNF-α and MMP. Simonaro et al. demonstrated that inactivation of TLR4 in MPS
VII mice reduced serum TNF-α levels and provided a significant positive effect on the orientation
of column structure in their growth plate regions, leading to improvement of bone length [26].
Moreover, this group also reported that an anti-inflammatory drug, pentosan polysulfate, improved
column structure in the growth plate although storage materials remained in chondrocytes [28].
These data suggest that GAG accumulation in ECM and successive inflammation in cartilage leads to
worsening skeletal dysplasia in MPS. Immunohistochemical staining showed that total proteoglycans
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were highly accumulated in ECM from the femoral condyle of the knee in a severe type of MPS
IVA patient, compared to that in healthy controls [34]. Therefore, it is likely that administration of
endoglycosidase, thermostable keratanase, degrades and removes KS in ECM as well as the circulating
blood, more directly than GALNS and consequently improves bone abnormality in MPS IVA via some
anti-inflammatory effects.
We have developed a sensitive and quantitative method to measure KS in blood and urine
from human by LC-MS/MS, which can identify two types of disaccharide KS (mono-sulfated KS
and di-sulfated KS) [35]. The levels of KS in blood and urine correlate with the clinical severity of
patients with MPS IVA [4,36–38]. However, patients with MPS IVA treated with ERT did not show any
improvement in the bone lesion, although the level of urine KS was substantially decreased. In contrast,
blood KS levels remained unchanged [4,39,40]. Urine and blood GAG, including KS, are likely to come
from a different origin [41,42].
In this study, we found that MPS IVA mice have significantly high levels of mono-sulfated KS
in blood, compared to heterozygous mice. We have monitored mono-sulfated KS level in the blood,
correlating with the improvement of bone pathology in MPS IVA mice. Therefore, blood KS levels
may be a more useful biomarker to evaluate treatment efficacy on bone lesions of these patients than
urinary KS levels.
In this study, we administered 2 U/kg of thermostable keratanase into MPS IVA mice three
times, resulting in the improvement of the bone pathology at the growth plate region when we
started treatment of newborns. To maximize therapeutic efficacy of thermostable keratanase, further
studies are required with consideration of the following factors: (i) dose-dependent administration,
(ii) age-dependent administration, and (iii) frequency and duration of administration. A higher
dose than 2 U/kg would be allowed since no apparent toxicity was noted in the preliminary toxicity
study. We need to consider that the use of a non-mammalian enzyme may evoke a serious immune
response. Development of immunosuppression strategies will be required, such as biodegradable
biomaterials (like PEGylation) encapsulating the enzyme. A PEGylated drug derived from a bacterial
enzyme is approved for phenylketonuria. This drug affected decreasing blood phenylalanine levels
but produced IgG and IgM antibodies against PEG [43]. Other immunosuppressing procedures still
should be considered.
It is notable that the proof of therapeutic efficacy with thermostable keratanase in MPS IVA mice
indicates that other bacterial GAG endoglycosidases such as chondroitinase ABC, chondroitinase B, or
heparinase would be applicable to treat other types of MPS. Successful completion of further study
should provide a significant impact on the MPS field.
In conclusion, administration of thermostable keratanase reduced levels of serum KS and
ameliorated the skeletal abnormalities of MPS IVA mice. Our novel, innovative therapy “SDET”
provides a potential approach to break down KS in the bloodstream and possibly the ECM and
consequently clears the accumulation of KS in multiple tissues, including cartilage, the region that ERT
has little effect on.
4. Materials and Methods
4.1. Production of Thermostable Keratanase from Bacillus circulans KsT202
Thermostable keratanase was extracted from B. circulans as previously described [29]. Briefly,
KsT202 was inoculated in medium (1% peptone, 0.75% Brewery’s yeast extract, 0.25% fish meal extract,
0.5% KH2 PO4 , 0.02% MgSO4 ·7H2 O, 0.1% NaCl, 150 ppm Adecanol LG-109, and 0.5% shark cartilage
KS, pH7.5), and cultured at 37 ◦ C. Two hundred grams of frozen bacteria pellets obtained from 20 L of
culture was resuspended in 1 L of 100 mM phosphate buffer, pH7.2 and treated with both lysozyme
(50 µg/mL) and DNase (4 µg/mL) for 60 min at 37 ◦ C. Then 3 L of cold 33 mM phosphate buffer was
added and centrifuged. The supernatant was collected and applied to a DEAE cellulose DE52 column
(Whatman, Maidstone, UK) equilibrated with 10 mM Tris-HCl, pH7.2. The enzyme fraction was eluted
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up to 0.4 M NaCl gradient. After the addition of NaCl to a final concentration of 4 M, the enzyme
fraction was applied to a phenyl sepharose 6 fast flow column (GE Healthcare, IL, US), equilibrated
with the 10 mM phosphate buffer, 4 M NaCl, pH7.2. The enzyme fraction was eluted using 4 to 0 M
NaCl linear gradient, followed by dialyzation against 100 mM sodium acetate, pH6.0. To remove
endotoxin, the enzyme was applied to an Endo Trap HD column (Hyglos GmbH, Munich, Germany)
equilibrated with 0.02 M HEPES, 0.15 M NaCl and 0.1 mM CaCl2 , pH7.4. Then, flow-through fractions
were applied to the regenerated Endo Trap HD column repeatedly. Finally, the enzyme fraction was
buffer exchanged with ultrafiltration to phosphate buffered saline (PBS) and stored at under −80 ◦ C
until use.
4.2. Keratanase Assay, Endotoxin Assay, and Protein Assay
The keratanase assay was carried out according to the method of Park and Johnson [44] and
performed as previously described [29]. The endotoxin concentration was measured by Endospecy
ES-50M (Seikagaku Corp., Tokyo, Japan). The protein concentration was measured by Lowry assay or
micro BCA assay (Thermo Fisher Scientific, Waltham, MA, USA). Bovine serum albumin was used as a
reference standard.
4.3. 3-Dimensional Chondrocyte Cell Culture
Chondrocyte cells derived from a MPS IVA patient was maintained at 37 ◦ C in a 5% CO2 incubator
in CBM™ Basal Medium containing CGM™ SingleQuots™ Kit (chondrocyte culture medium) (Lonza,
Walkersville, MD, USA). The 3-dimensional (3-D) chondrocyte cell culture was followed according
to the supplier’s instruction. Briefly, the cells were diluted with 1.2% sodium alginate solution, and
the cell suspension was dropped into CaCl2 solution in 6-well plate with a 22G needle. The dropped
beads were washed by 155 mM NaCl several times and incubated in chondrocyte growth medium
for 28 days. Then, the cells were treated with 1 µU/mL thermostable keratanase for 72 h incubation.
After the end of incubation, the beads were depolymerized with 55 mM sodium citrate solution and
washed with PBS 3 times. The cell pellets were sonicated on ice and stored at −20 ◦ C until processing
for GAG assay.
4.4. Preliminary Toxicity Study of Thermostable Keratanase in Mice
C57BL/6J mice (6 males) at 6–7 weeks of age were weekly treated with 250 U/kg of thermostable
keratanase via a tail vein and monitored until day 25. As for control groups, 3 male mice were treated
with saline. The behavioral signs of mice were observed until 1 h after administration. All animal cares
and experiments were approved by the Institutional Animal Care and Use Committee of Seikagaku
Corporation and carried out by relevant guidelines and regulations.
4.5. Intravenous Injection of Thermostable Keratanase to MPS IVA Mice
The generation of MPS IVA knockout (KO) mouse (Galns−/− ) in C57BL/6 background was described
previously [45]. Genotype was determined by PCR on day 14. Three treatment studies were performed.
(1) In single administration study, MPS IVA mice at 8 weeks of age received a single intravenous
injection of 2 U/kg thermostable keratanase via the tail vein. Serum KS and diHS-0S levels were
monitored at weeks 0 (before treatment), 1, 2, 3, 4, and 8. Untreated mice received PBS in the same
manner. Blood samples were collected from the superficial temporal vein at the time points of 8
(before treatment), 9, 10, 11, 12, and 16 weeks of age. (2) In the neonatal administration study, at 1 or
2 days after birth, neonatal MPS IVA mice were treated with 2 U/kg thermostable keratanase via a
superficial temporal vein and injected with 2 U/kg of this enzyme intravenously at 4 and 8 weeks of
age and monitored until 12 weeks of age. PBS was administered into MPS IVA mice (untreated) and
heterozygous mice (control) in the same manner. Blood samples were collected from the superficial
temporal vein at the time points of 8 and 12 weeks of age. Tissues were collected at 12 weeks of age.
(3) In the tissue levels of KS measurement study, MPS IVA mice were treated with 2U/kg thermostable
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keratanase intravenously at 4 weeks of age, and tissues were collected after 24 h of administration.
At each time point, approximately 100 µL of blood was collected in separator tubes (BD, Franklin Lakes,
NJ, USA). The blood was centrifuged at 8000 rpm for 10 min, and serum separated was kept at −20 ◦ C
until performing GAG assay by LC-MS/MS. At necropsy, mice were euthanized in a CO2 chamber
and perfused with 20 mL of 0.9% saline. Liver and spleen were collected and stored at −80 ◦ C until
processing for GAG assay. Bone tissues were stored in 10% neutral buffered formalin until histological
processing. All animal cares and experiments were approved by the Institutional Animal Care and
Use Committee of Nemours/Alfred I. duPont Hospital for Children (Protocol#: NBR 2014-003, Date:
26-3-2014).
4.6. Extraction of GAG from Tissue
We previously developed the GAG extraction method from various tissues in mice [46]. Briefly,
dissected liver and spleen were frozen in liquid nitrogen and homogenized with acetone using a
homogenizer. After centrifugation, the obtained tissue acetone powder was dried up under centrifugal
vacuum concentrator. The defatted tissue was suspended in 0.5 M NaOH and incubated at 50 ◦ C for
2 h to remove GAG polymers from its proteoglycan core protein. After neutralization with 1 M HCl,
NaCl was added to a final concentration of 3 M. Insoluble materials were removed by centrifugation,
and the pH of the supernatant was adjusted below 1.0 with 1 M HCl. The precipitate was removed by
centrifugation, and the supernatant was neutralized with 1 M NaOH. The GAG was precipitated by
the addition of two volumes of ethanol containing 1.3% potassium acetate. After centrifugation, the
precipitated pellet was washed by 80% cold ethanol and dissolved in distilled water.
4.7. GAG Assay
Serum and tissue GAG level were measured by LC-MS/MS as described previously [35,47–50].
Briefly, serum and homogenated tissues were filtered by 96 well omega 10K filter plate (Pall Corporation,
Port Washington, NY, USA). Mixture solution containing 5 µg/mL internal standard (IS), 1 mU
heparitinase, 1 mU chondroitinase ABC and 1 mU keratanase II was added to the filter plate, and
samples were incubated at 37 ◦ C water bath overnight. Then, the samples were centrifuged for 15 min
at 2500× g, and 10 µL of filtered samples were injected to the apparatus consisted of a 1290 Infinity
LC system with a 6460 triple quad mass spectrometer (Agilent Technologies, Palo Alto, CA, USA).
Each disaccharide was separated on a Hypercarb column (2.0 mm i.d. 50 mm length; 5 µm particles;
Thermo Fisher Scientific, Waltham, MA, USA), maintained at 60◦ C. The mobile phase was a gradient
elution of 5 mM ammonium acetate, pH 11.0 (solvent A) to 100% acetonitrile (solvent B). The flow
rate was 0.7 mL/min, and the gradient was as follows: 0 min 100% solvent A, 1 min 70% solvent
A, 2 min 70% solution A, 2.20 min 0% solvent A, 2.60 min 0% solvent A, 2.61 min 100% solvent
A, 5 min 100% solvent A. The mass spectrometer was operated with electrospray ionization in the
negative ion mode (Agilent Jet Stream technology). Each disaccharide was quantified by specific
m/z precursor and product ions [IS, 354.3→193.1; mono-sulfated KS, 462→97; diHS-0S 378.3→175.1;
diHS-NS 416.0→138.1; Di-6S 458.4→282.1]. Chondrosine was used as an IS.
4.8. Histopathological Staining
Toluidine blue staining and hematoxylin and eosin staining were performed as previously
described [51]. Briefly, knee joint (femur and tibia) was collected from MPS IVA mice at 12 weeks old
to evaluate the therapeutic effects of thermostable keratanase by light microscopy. For toluidine blue
staining, tissues were fixed in 4% glutaraldehyde, 2% paraformaldehyde in PBS, and post-fixed in
osmium tetroxide and embedded in Spurr’s resin. Then, toluidine blue-stained 0.5-µm-thick sections
were prepared. For hematoxylin and eosin staining, tissues were fixed in 10% neutral buffered formalin
and embedded in paraffin. Then, hematoxylin and eosin stained 3-µm-thick sections were prepared.
Histopathological findings were evaluated between the controls and treatment groups. The degrees of
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chondrocyte vacuolation and chondrocyte alignment of the growth plates were scored. “None” was
score 0 (−), “minimal” was score 1 (+), “moderate” was score 2 (++), and “severe” was score 3 (+++).
4.9. Statistical Analysis
All data were expressed as means and standard deviations (SD). Two comparison tests and
multiple comparison tests were performed by unpaired t-test or one-way ANOVA with the Bonferroni’s
post-hoc test using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA), respectively.
The statistical significance of difference was considered as p < 0.05.
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